Vanguard Group Inc Pep Gen Inc. Transaction History

Vanguard Group Inc

$5.57 Trillion
Q4 2024

A detailed history of Vanguard Group Inc transactions in Pep Gen Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 912,670 shares of PEPG stock, worth $1.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

912,670

Previous 919,415 0.73%

Holding current value

$1.31 Million

Previous $7.86 Million 55.88%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	$3.63 - $9.93 $24,484 - $66,977	-6,745 Reduced 0.73%	912,670 $3.47 Million
Q3 2024 Nov 13, 2024	BUY	$7.75 - $18.55 $124,170 - $297,208	16,022 Added 1.77%	919,415 $7.86 Million
Q2 2024 Aug 13, 2024	BUY	$10.54 - $18.14 $558,071 - $960,476	52,948 Added 6.23%	903,393 $14.4 Million
Q1 2024 May 10, 2024	BUY	$6.63 - $17.3 $2.28 Million - $5.96 Million	344,266 Added 68.01%	850,445 $12.5 Million
Q4 2023 Feb 14, 2024	BUY	$3.86 - $7.96 $13,069 - $26,952	3,386 Added 0.67%	506,179 $3.44 Million
Q3 2023 Nov 14, 2023	BUY	$5.0 - $9.09 $7,345 - $13,353	1,469 Added 0.29%	502,793 $2.55 Million
Q2 2023 Aug 14, 2023	SELL	$8.94 - $16.39 $214,381 - $393,032	-23,980 Reduced 4.56%	501,324 $4.48 Million
Q1 2023 May 15, 2023	BUY	$11.44 - $17.7 $93,808 - $145,140	8,200 Added 1.59%	525,304 $6.42 Million
Q4 2022 Feb 10, 2023	BUY	$9.31 - $16.57 $429,349 - $764,158	46,117 Added 9.79%	517,104 $6.91 Million
Q3 2022 Nov 14, 2022	BUY	$4.86 - $12.75 $53,037 - $139,140	10,913 Added 2.37%	470,987 $4.28 Million
Q2 2022 Aug 12, 2022	BUY	$9.0 - $12.89 $4.14 Million - $5.93 Million	460,074 New	460,074 $4.57 Million

Others Institutions Holding PEPG

# of Institutions

Shares Held

24.7M

Call Options Held

Put Options Held

15K

View Full List

About PepGen Inc.

Ticker PEPG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,631,900
Market Cap $34M
Description
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is a...

More about PEPG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Pep Gen Inc. Transaction History